Treatment with the mTOR inhibitor temsirolimus in patients with malignant PEComa

MeSH terms

• Female
• Heart Neoplasms / drug therapy*
• Heart Neoplasms / metabolism
• Heart Neoplasms / secondary
• Humans
• Intracellular Signaling Peptides and Proteins / antagonists & inhibitors*
• Intracellular Signaling Peptides and Proteins / metabolism
• Lung Neoplasms / drug therapy*
• Lung Neoplasms / metabolism
• Lung Neoplasms / secondary
• Perivascular Epithelioid Cell Neoplasms / drug therapy*
• Perivascular Epithelioid Cell Neoplasms / metabolism
• Perivascular Epithelioid Cell Neoplasms / pathology
• Protein Kinase Inhibitors / therapeutic use*
• Protein Serine-Threonine Kinases / antagonists & inhibitors*
• Protein Serine-Threonine Kinases / metabolism
• Sirolimus / analogs & derivatives*
• Sirolimus / therapeutic use
• TOR Serine-Threonine Kinases
• Tomography, X-Ray Computed
• Treatment Outcome
• Uterine Neoplasms / drug therapy*
• Uterine Neoplasms / metabolism
• Uterine Neoplasms / pathology